Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ALBERTO BESSUDO

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1003888074
CMS profile
226877
Location
ENCINITAS, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$13,587.41

249 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $6,420.00 1
Food and Beverage $6,217.72 244
Travel and Lodging $916.63 2
Education $33.06 2

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
GENZYME CORPORATION $7,777.33 9
Alexion Pharmaceuticals, Inc. $567.27 19
E.R. Squibb & Sons, L.L.C. $515.21 18
Novartis Pharmaceuticals Corporation $380.59 17
PFIZER INC. $343.93 19
Genmab U.S., Inc. $328.87 3
Merck Sharp & Dohme LLC $246.35 11
Celgene Corporation $241.73 14
ABBVIE INC. $225.42 10
GlaxoSmithKline, LLC. $214.08 13
AstraZeneca Pharmaceuticals LP $211.23 9
Janssen Biotech, Inc. $206.24 9
Aveo Pharmaceuticals, Inc. $205.70 4
Daiichi Sankyo Inc. $178.53 9
ARRAY BIOPHARMA INC $178.38 9
SOBI, INC $141.32 7
Gilead Sciences, Inc. $137.57 7
Eisai Inc. $123.75 6
Exelixis Inc. $111.95 5
Verity Pharmaceuticals Inc. $106.21 4
Regeneron Healthcare Solutions, Inc. $80.31 3
Rigel Pharmaceuticals, Inc. $69.28 2
PharmaEssentia USA Corporation $68.94 2
Dendreon Pharmaceuticals LLC $66.37 2
Bayer Healthcare Pharmaceuticals Inc. $61.74 3
Ipsen Biopharmaceuticals, Inc $60.52 2
Edwards Lifesciences Corporation $57.54 1
Agios Pharmaceuticals, Inc. $57.12 3
Genentech USA, Inc. $48.37 2
Karyopharm Therapeutics Inc. $47.98 2
SERVIER PHARMACEUTICALS LLC $42.37 2
Incyte Corporation $39.64 2
EMD Serono, Inc. $39.60 2
Deciphera Pharmaceuticals Inc. $35.80 1
TerSera Therapeutics LLC $33.27 1
Boehringer Ingelheim Pharmaceuticals, Inc. $31.58 1
Mirati Therapeutics, Inc. $30.38 1
Blueprint Medicines Corporation $28.93 1
Kite Pharma, Inc. $26.77 1
BeiGene USA, Inc. $26.27 1
Tempus AI, Inc $25.57 1
Takeda Pharmaceuticals U.S.A., Inc. $24.40 1
Fennec Pharmaceuticals, Inc. $24.16 3
Astellas Pharma US Inc $22.05 1
Pharmacosmos Therapeutics Inc. $20.45 1
Coherus Biosciences Inc. $17.59 1
ACCORD HEALTHCARE, INC. $16.23 1
Cumberland Pharmaceuticals, Inc. $14.61 1
Octapharma USA, Inc. $14.42 1
Lilly USA, LLC $13.49 1

Page 5 of 5; records 201–249 of 249 matching records. This page contains 49 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ALBERTO BESSUDO

NPI 1003888074 · CMS profile ID 226877

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

ENCINITAS, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 5 of 5; records 201–249 of 249 matching records. This page contains 49 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1003888074?year=2024&recipient=provider&page=5#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ALBERTO BESSUDO, NPI 1003888074, CMS profile ID 226877. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 5; records 201–249 of 249 matching records. This page contains 49 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1003888074?year=2024&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). ALBERTO BESSUDO, NPI 1003888074, CMS profile ID 226877. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 5; records 201–249 of 249 matching records. This page contains 49 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1003888074?year=2024&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
ALBERTO BESSUDO, NPI 1003888074, CMS profile ID 226877, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 5 of 5; records 201–249 of 249 matching records. This page contains 49 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1003888074?year=2024&recipient=provider&page=5#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

249 matching records · $13,587.41 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 249 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 201–249 of 249.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Gilead Sciences, Inc. $19.3803/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133805469 CMS
Merck Sharp & Dohme LLC $16.8203/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141910586 CMS
Novartis Pharmaceuticals Corporation $32.3303/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086706513 CMS
Verity Pharmaceuticals Inc. $26.5603/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1080598072 CMS
Incyte Corporation $19.9803/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141246924 CMS
Alexion Pharmaceuticals, Inc. $19.2003/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1093924625 CMS
E.R. Squibb & Sons, L.L.C. $21.1503/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101256149 CMS
Verity Pharmaceuticals Inc. $25.2103/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1080598076 CMS
ABBVIE INC. $23.8203/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103317546 CMS
Blueprint Medicines Corporation $28.9302/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147444633 CMS
ABBVIE INC. $20.8002/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103317544 CMS
Eisai Inc. $15.9702/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110727481 CMS
Genentech USA, Inc. $20.0502/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1132973557 CMS
Agios Pharmaceuticals, Inc. $24.0602/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149646158 CMS
Daiichi Sankyo Inc. $8.9102/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089399865 CMS
Octapharma USA, Inc. $14.4202/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1142312729 CMS
GENZYME CORPORATION $38.0802/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139630581 CMS
Eisai Inc. $17.9502/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110727479 CMS
Daiichi Sankyo Inc. $24.0802/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089399867 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $31.5802/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117834350 CMS
PFIZER INC. $34.0002/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131301291 CMS
PFIZER INC. $0.3202/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131314924 CMS
E.R. Squibb & Sons, L.L.C. $22.5102/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101256147 CMS
Edwards Lifesciences Corporation $57.5402/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1138794900 CMS
Genmab U.S., Inc. $89.5002/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1126823916 CMS
PFIZER INC. $29.0402/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131025324 CMS
PFIZER INC. $5.3602/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131032411 CMS
Gilead Sciences, Inc. $25.7102/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133805467 CMS
PFIZER INC. $5.9001/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131403831 CMS
AstraZeneca Pharmaceuticals LP $24.5301/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104718103 CMS
Novartis Pharmaceuticals Corporation $20.0201/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086706505 CMS
GlaxoSmithKline, LLC. $8.5201/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115840092 CMS
GlaxoSmithKline, LLC. $1.7501/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116413293 CMS
PFIZER INC. $8.1401/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131028992 CMS
Bayer Healthcare Pharmaceuticals Inc. $24.3001/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086123386 CMS
GENZYME CORPORATION $118.9501/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139630575 CMS
Verity Pharmaceuticals Inc. $29.2801/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1080598080 CMS
Karyopharm Therapeutics Inc. $33.6401/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145527627 CMS
AstraZeneca Pharmaceuticals LP $20.5101/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104322316 CMS
Janssen Biotech, Inc. $19.0701/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078294251 CMS
Karyopharm Therapeutics Inc. $14.3401/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145527629 CMS
Daiichi Sankyo Inc. $18.3601/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089399859 CMS
Daiichi Sankyo Inc. $0.6301/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089399861 CMS
Janssen Biotech, Inc. $25.3401/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078294475 CMS
GlaxoSmithKline, LLC. $29.7101/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116520848 CMS
Exelixis Inc. $15.5601/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1138554542 CMS
E.R. Squibb & Sons, L.L.C. $24.2601/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101256137 CMS
Merck Sharp & Dohme LLC $24.3001/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141573565 CMS
Novartis Pharmaceuticals Corporation $27.7901/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086706501 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $4,369.79 197
PY2020 $10,425.35 53
PY2021 $4,671.36 92
PY2022 $9,536.82 161
PY2023 $8,076.24 193
PY2024 $13,587.41 249
PY2025 $3,923.74 152

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $96,620.75 31
PY2024 Recipient $746.00 1
PY2024 Principal investigator $131,888.56 35
PY2023 Principal investigator $417,974.29 45
PY2022 Principal investigator $85,479.23 11
PY2021 Principal investigator $524,383.39 34
PY2020 Principal investigator $1,145,676.90 254
PY2019 Principal investigator $1,538,125.60 302

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

31 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $650.00 12/22/2025 Non-covered Recipient Entity
CA Cancer Associates Res Excel
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228713222
Principal investigator 1 PFIZER INC. $1,300.00 11/24/2025 Non-covered Recipient Entity
CA Cancer Associates Res Excel
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228713404
Principal investigator 1 PFIZER INC. $7,152.00 11/14/2025 Non-covered Recipient Entity
California Cancer Associates for Research and Excellence Inc
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228818128
Principal investigator 1 PFIZER INC. $650.00 10/27/2025 Non-covered Recipient Entity
CA Cancer Associates Res Excel
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228713402
Principal investigator 1 PFIZER INC. $2,384.00 10/09/2025 Non-covered Recipient Entity
California Cancer Associates for Research and Excellence Inc
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228824844
Principal investigator 1 GlaxoSmithKline, LLC. $345.00 09/26/2025 Non-covered Recipient Entity
ADVARRA
A PROSPECTIVE, REAL-WORLD, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT No dispute reported 06/30/2026 1192105034
Principal investigator 1 GlaxoSmithKline, LLC. $250.00 09/18/2025 Non-covered Recipient Entity
CALIFORNIA CANCER ASSOCIATES FOR RESEARCH AND EXCELLENCE INC
AN OPEN-LABEL, MULTICENTER, LONG-TERM TREATMENT EXTENSION STUDY IN SUB No dispute reported 06/30/2026 1192103525
Principal investigator 1 GlaxoSmithKline, LLC. $1,405.75 09/18/2025 Non-covered Recipient Entity
CALIFORNIA CANCER ASSOCIATES FOR RESEARCH AND EXCELLENCE INC
AN OPEN-LABEL, MULTICENTER, LONG-TERM TREATMENT EXTENSION STUDY IN SUB No dispute reported 06/30/2026 1192103532
Principal investigator 1 PFIZER INC. $38,167.50 09/16/2025 Non-covered Recipient Entity
California Cancer Associates for Research and Excellence Inc
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228835972
Principal investigator 1 PFIZER INC. $2,384.00 09/09/2025 Non-covered Recipient Entity
California Cancer Associates for Research and Excellence Inc
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228836036
Principal investigator 1 GlaxoSmithKline, LLC. $3,800.00 08/27/2025 Non-covered Recipient Entity
INTERSPOND LLC
A PROSPECTIVE, REAL-WORLD, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT No dispute reported 06/30/2026 1192103490
Principal investigator 1 PFIZER INC. $2,384.00 08/06/2025 Non-covered Recipient Entity
California Cancer Associates for Research and Excellence Inc
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228843601
Principal investigator 1 PFIZER INC. $1,300.00 07/29/2025 Non-covered Recipient Entity
CA Cancer Associates Res Excel
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228713220
Principal investigator 1 GlaxoSmithKline, LLC. $750.00 07/22/2025 Non-covered Recipient Entity
INTERSPOND LLC
A PROSPECTIVE, REAL-WORLD, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT No dispute reported 06/30/2026 1192103495
Principal investigator 1 Karyopharm Therapeutics Inc. $2,694.00 06/20/2025 Non-covered Recipient Entity
California Cancer Assocs.for Research and Excellence
A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1246662824
Principal investigator 1 PFIZER INC. $2,384.00 06/06/2025 Non-covered Recipient Entity
California Cancer Associates for Research and Excellence Inc
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228852098
Principal investigator 1 GlaxoSmithKline, LLC. $1,405.75 06/05/2025 Non-covered Recipient Entity
CALIFORNIA CANCER ASSOCIATES FOR RESEARCH AND EXCELLENCE INC
AN OPEN-LABEL, MULTICENTER, LONG-TERM TREATMENT EXTENSION STUDY IN SUB No dispute reported 06/30/2026 1192103519
Principal investigator 1 PFIZER INC. $2,384.00 05/14/2025 Non-covered Recipient Entity
California Cancer Associates for Research and Excellence Inc
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228857674
Principal investigator 1 PFIZER INC. $2,384.00 05/01/2025 Non-covered Recipient Entity
California Cancer Associates for Research and Excellence Inc
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228857721
Principal investigator 1 F. Hoffmann-La Roche AG $532.80 04/16/2025 Non-covered Recipient Entity
CALIFORNIA CANCER ASSOCIATES FOR RESEARCH AND EXCELLENCE
Ph III GDC 199 GA101 vs GChl in CLL with comorbidities No dispute reported 06/30/2026 1211582487
Principal investigator 1 F. Hoffmann-La Roche AG $624.96 04/16/2025 Non-covered Recipient Entity
CALIFORNIA CANCER ASSOCIATES FOR RESEARCH AND EXCELLENCE
Ph III GDC 199 GA101 vs GChl in CLL with comorbidities No dispute reported 06/30/2026 1211582491
Principal investigator 1 Eli Lilly and Company $76.95 04/08/2025 Non-covered Recipient Entity
CANCER CAR ASSOCIATES OF FRESNO MEDICAL GROUP
A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB (LOXO-305) VERSUS IBRUTINIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (BRUIN-CLL-314) No dispute reported 06/30/2026 1187876155
Principal investigator 1 PFIZER INC. $1,625.00 03/31/2025 Non-covered Recipient Entity
CA Cancer Associates Res Excel
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228840946
Principal investigator 1 PFIZER INC. $2,384.00 03/14/2025 Non-covered Recipient Entity
California Cancer Associates for Research and Excellence Inc
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228862508
Principal investigator 1 PFIZER INC. $2,384.00 02/14/2025 Non-covered Recipient Entity
California Cancer Associates for Research and Excellence Inc
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228835977
Principal investigator 1 Eli Lilly and Company $8,393.26 01/22/2025 Non-covered Recipient Entity
CANCER CAR ASSOCIATES OF FRESNO MEDICAL GROUP
A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB (LOXO-305) VERSUS IBRUTINIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (BRUIN-CLL-314) No dispute reported 06/30/2026 1187875425
Principal investigator 1 GlaxoSmithKline, LLC. $1,405.75 01/16/2025 Non-covered Recipient Entity
CALIFORNIA CANCER ASSOCIATES FOR RESEARCH AND EXCELLENCE INC
AN OPEN-LABEL, MULTICENTER, LONG-TERM TREATMENT EXTENSION STUDY IN SUB No dispute reported 06/30/2026 1192103506
Principal investigator 1 PFIZER INC. $2,384.00 01/15/2025 Non-covered Recipient Entity
California Cancer Associates for Research and Excellence Inc
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228863630
Principal investigator 1 GlaxoSmithKline, LLC. $854.83 01/09/2025 Non-covered Recipient Entity
CALIFORNIA CANCER ASSOCIATES FOR RESEARCH AND EXCELLENCE INC
AN OPEN-LABEL, MULTICENTER, LONG-TERM TREATMENT EXTENSION STUDY IN SUB No dispute reported 06/30/2026 1192103501
Principal investigator 1 GlaxoSmithKline, LLC. $550.92 01/09/2025 Non-covered Recipient Entity
CALIFORNIA CANCER ASSOCIATES FOR RESEARCH AND EXCELLENCE INC
AN OPEN-LABEL, MULTICENTER, LONG-TERM TREATMENT EXTENSION STUDY IN SUB No dispute reported 06/30/2026 1192103512
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,230.28 01/09/2025 Non-covered Recipient Entity
CALIFORNIA CANCER ASSOCIATES FOR RESEARCH AND EXCELLENCE
A PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY AND PHARMACOKINETICS OF REGN3767 (ANTI-LAG-3 MAB) ADMINISTERED ALONE OR IN COMBINATION WITH REGN2810 (ANTI-PD-1 MAB) IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1184147345